Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings [Seeking Alpha]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Seeking Alpha
Follow Play 17min Summary Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and early sales success, Madrigal's Q3 earnings will be crucial in determining Rezdiffra's commercial viability and stock performance. The potential for Rezdiffra to achieve blockbuster status is tempered by its high cost and the emerging threat of GLP-1 agonists in the MASH market. Given the uncertainties and competitive landscape, I am downgrading Madrigal from a "Buy" to a "Hold" ahead of Q3 earnings. Klaus Vedfelt Investment Overview - brief history of Madrigal, it's MASH drug Approval, & it's share price volatility) Madrigal Pharmaceuticals ( NASDAQ: MDGL secured the first-ever approval for a drug targeting the indication of nonalcoholic steatohepatitis (NASH) - since renamed metabolic dysfunction-associated If you like what you have just
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade [Yahoo! Finance]Yahoo! Finance
- 1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More [Yahoo! Finance]Yahoo! Finance
- Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy [Yahoo! Finance]Yahoo! Finance